InvestorsObserver
Sign Up Login

MYMD Mymd Pharmaceuticals Inc

$2.76 $-0.05 (-1.74%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

MYMD Stock Analysis Overview

What this means: Mymd Pharmaceuticals Inc (MYMD) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives MYMD a rank of 12. Our methodology considers analysis of the company's financial situation and how it has traded recently. MYMD rank of 12 means that it ranks below 88% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

MYMD Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

MYMD Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

MYMD Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

MYMD Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

MYMD Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

MYMD Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

MYMD Stock Analysis Overview

What this means: Mymd Pharmaceuticals Inc (MYMD) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives MYMD a rank of 12. Our methodology considers analysis of the company's financial situation and how it has traded recently. MYMD rank of 12 means that it ranks below 88% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full MYMD report

MYMD Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

MYMD Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

MYMD Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

MYMD Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

MYMD Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

MYMD Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Mymd Pharmaceuticals Inc (MYMD) Analyst Forecast

MYMD Price, Volume, Earnings, and Dividend Date

  • Last Price $2.76
  • Previous Close $2.81
  • Change $-0.05
  • Open $2.76
  • Volume 284
  • Avg. Volume (100-day) 166,599
  • Market Cap 6,062,946
  • Days Range 2.7611 - 2.7611
  • 52-week Range 2 - 70.5
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS 1.8
  • Earnings Date 05/20/24
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.515
  • PEG Ratio —

Mymd Pharmaceuticals Inc (MYMD) Company Description

MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia.

Mymd Pharmaceuticals Inc (MYMD) Stock Chart

View Interactive MYMD chart

My Watchlists

Top Stocks in Biotechnology